Rock Springs Capital Management LP Ascendis Pharma A/S Transaction History

Rock Springs Capital Management LP

$2.94 Billion
Q3 2024

A detailed history of Rock Springs Capital Management LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Rock Springs Capital Management LP holds 325,000 shares of ASND stock, worth $42.2 Million. This represents 1.65% of its overall portfolio holdings.

Number of Shares

325,000

Previous 290,000 12.07%

Holding current value

$42.2 Million

Previous $39.6 Million 22.72%

% of portfolio

1.65%

Previous 1.23%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $3.96 Million - $5.37 Million	35,000 Added 12.07%	325,000 $48.5 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $11.7 Million - $17.3 Million	-135,500 Reduced 31.84%	290,000 $36.5 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $624,640 - $940,880	8,000 Added 1.92%	425,500 $39.6 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $1.79 Million - $2.38 Million	17,500 Added 4.38%	417,500 $49 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $18.8 Million - $29.5 Million	166,500 Added 71.31%	400,000 $63.8 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $2.69 Million - $3.09 Million	20,000 Added 9.37%	233,500 $36 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $1.86 Million - $3.9 Million	-30,000 Reduced 12.32%	213,500 $25.1 Million
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $2.34 Million - $2.96 Million	-40,000 Reduced 14.11%	243,500 $16.2 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $136,430 - $238,140	3,500 Added 1.25%	283,500 $18.5 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $7.53 Million - $10.4 Million	280,000	280,000 $10.2 Million

Others Institutions Holding ASND

# of Institutions

243

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.24B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Ascendis Pharma A/S Transaction History